Advisory Research Inc Bluebird Bio, Inc. Transaction History

Advisory Research Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Aug 14, 2019	SELL	$75.84 - $105.21 $210,000 - $291,326	-2,769 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$64.44 - $104.11 $178,434 - $288,280	2,769 New	2,769 $436,000
Q3 2018 Nov 13, 2018	SELL	$88.86 - $117.49 $662,629 - $876,122	-7,457 Closed	0 $0
Q2 2018 Aug 14, 2018	SELL	$99.64 - $127.59 $131,026 - $167,780	-1,315 Reduced 14.99%	7,457 $1.17 Million
Q1 2018 May 15, 2018	SELL	$105.8 - $150.94 $452,718 - $645,872	-4,279 Reduced 32.79%	8,772 $1.5 Million
Q4 2017 Feb 08, 2018	SELL	$81.25 - $130.7 $462,881 - $744,597	-5,697 Reduced 30.39%	13,051 $2.32 Million
Q3 2017 Nov 14, 2017	BUY	$57.74 - $91.42 $1.08 Million - $1.71 Million	18,748	18,748 $2.58 Million

27M

191K

299K

Ticker BLUE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,121,800
Market Cap $561M
Description
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...

Get notified when there are updates to the investment portfolio of Advisory Research Inc, based on Form 13F filings with the SEC.

Stay updated on Advisory Research Inc with notifications on news.